Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.

ABSTRACT:

Introduction

Cancer anorexia-cachexia syndrome (CACS) is associated with increased morbidity and mortality. Anamorelin is a novel, orally active ghrelin receptor agonist in clinical development for the treatment of CACS in NSCLC. The aim of this review is to summarize preclinical and clinical studies evaluating anamorelin as a potential promising treatment for CACS in NSCLC.

Areas covered

Pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability of anamorelin for the treatment of CACS in NSCLC were reviewed. Anamorelin administration may lead to increases in food intake, body weight and lean body mass, and a stimulatory effect on growth hormone secretion in NSCLC patients. Anamorelin is well tolerated with no dose-limiting toxicities ident

SUBMITTER: Zhang H 

PROVIDER: S-EPMC4677053 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature